**Supplementary table 1: The number and percentage of patients in different visual outcome categories along the plasma exchange treatments**

Visual outcome (VA)	Onset	Before PE	1st PE	2nd PE	3rd PE	4th PE	5th PE	1-month
NLP	19 (51.4%)	13 (35.1%)	6 (16.2%)	6 (16.2%)	6 (16.2%)	6 (16.2%)	6 (16.2%)	6 (16.2%)
LP	3 (8.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HM	4 (10.8%)	3 (8.1%)	2 (5.4%)	3 (8.1%)	2 (5.4%)	2 (5.4%)	1 (2.7%)	1 (2.7%)
CF	3 (8.1%)	8 (21.6%)	10 (27.0%)	9 (24.3%)	8 (21.6%)	7 (18.9%)	7 (18.9%)	7 (18.9%)
20/800 ≥ VA > 20/2000	1 (2.7%)	4 (10.8%)	5 (13.5%)	4 (10.8%)	5 (13.5%)	6 (16.2%)	6 (16.2%)	6 (16.2%)
20/200 ≥ VA > 20/800	7 (18.9%)	6 (16.2%)	7 (18.9%)	6 (16.2%)	7 (18.9%)	6 (16.2%)	7 (18.9%)	7 (18.9%)
20/60 ≥ VA > 20/200	0 (0.0%)	1 (2.7%)	4 (10.8%)	5 (13.5%)	3 (8.1%)	2 (5.4%)	0 (0.0%)	0 (0.0%)
20/30 ≥ VA > 20/60	0 (0.0%)	2 (5.4%)	2 (5.4%)	2 (5.4%)	4 (10.8%)	2 (5.4%)	3 (8.1%)	3 (8.1%)
Scotoma but VA better than 20/30	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.7%)	0 (0.0%)	3 (8.1%)	2 (5.4%)	2 (5.4%)
20/20	0 (0.0%)	0 (0.0%)	1 (2.7%)	1 (2.7%)	2 (5.4%)	3 (8.1%)	5 (13.5%)	5 (13.5%)
Adjusted p	/	> 0.999[a]	0.598[b]	0.191[b]	0.012[b]	0.001[b]	< 0.001[b]	> 0.999[c]

CF: finger counting; HM: hand motion; LP: Light perception; NLP: No light perception; PE: Plasma exchange; VA: Visual acuity; [a] compared to the onset; [b] compared to before PE; [c] compared to the fifth PE.

Supplementary figure 1: Individual logMAR VA changes of the studied eyes along the plasma exchange treatment period.

The logMAR VA of the 37 studied eyes at the onset, 1 day before PE therapy (after IVMP treatment), after each PE cycles and 1-month follow-up visit. PE: plasma exchange therapy; VA: visual acuity.

Supplementary figure 2: The correlation of visual acuity of the studied eyes before and after the plasma exchange treatment.

Majority of the VA after the fifth PE therapy was better than that before the PE treatment ($R^2 = 0.523$; $p < 0.001$). Only 3 eyes showed reduced VA and 7 eyes remained the same VA after the PE therapy. The data was presented as the logMAR VA. PE: plasma exchange therapy; VA: visual acuity. Solid line: the line representing the same VA before and after the PE treatment; Dotted line: the trend of the distribution of the data point in the graph.